TP53 and carcinoma: In a panel of human mutp53 cancer cell lines representing various conformational missense mutations and carcinoma entities, Simvastatin (32 μM for 48 h) downregulated mutp53 and simultaneously upregulated cleaved PARP, albeit to different degrees, in all lines tested, but failed to do so in p53 wildtype (WT) cancer cells (Fig. 1a).